Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

An Unusually Large Carbuncle of the Temporofacial Region

Published: Mon, 26 Jun 2017 12:00:00 EDT
How was this extensive carbuncle over the temporofacial region effectively managed?

Management of the Diabetic Patient Needing Emergency Surgery

Published: Mon, 26 Jun 2017 12:00:00 EDT
The emergency surgical patient with diabetes presents unique challenges, and is often considered high risk. What can be done to improve outcomes for these patients?
BJA Education

Severe Polyserositis Induced by PCV13 Vaccine

Published: Mon, 26 Jun 2017 12:00:00 EDT
Was the severe serositis in this 75-year-old woman an auto-inflammatory response to her recent vaccination with 13-valent pneumococcal conjugate vaccine?
Journal of Medical Case Reports

Delayed Second Dose Antibiotics for Patients With Sepsis

Published: Mon, 26 Jun 2017 12:00:00 EDT
How might delays in second antibiotic administration affect outcomes among patients admitted with sepsis?
Critical Care Medicine
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Gottlieb’s FDA to rethink targeted therapy regulation to speed development, drive down healthcare costs

Published: Wed, 21 Jun 2017 10:25:42 +0000
The FDA is working on a medical innovation development plan designed to lower healthcare costs by streamlining the path to market for targeted therapies and other novel drugs. Commissioner Scott Gottlieb, M.D., pitched the plan as a broad drive to ensure the FDA has the tools and policies to encourage and evaluate innovative therapies.

Apple Tree helps Big Apple biotech Syntimmune in $50M series B

Published: Wed, 21 Jun 2017 08:19:40 +0000
New York biotech Syntimmune has got off a beefy $50 million series B round as it looks to use the funds for its FcRn biology tests.

Flagship-backed Rubius raises $120M to take off-the-shelf red blood cell cancer therapeutics into the clinic

Published: Tue, 20 Jun 2017 15:21:37 +0000
Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic. The Flagship Pioneering-backed biotech is using its method for expressing proteins on allogeneic red blood cells to create candidates that hit multiple immuno-oncology targets.

Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura

Published: Tue, 20 Jun 2017 13:54:52 +0000
German Merck, fresh off it and partner Pfizer’s FDA approval for their checkpoint inhibitor Bavencio, and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.
Displaying results 17-20 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy